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ABSTRACT
BACKGROUND: Medication nonadherence is an imperative public health 
concern. Among patients with type 2 diabetes mellitus (T2DM), poor 
adherence to antidiabetic agents is strongly associated with suboptimal 
glycemic control. Poor adherence and hyperglycemia greatly increase 
diabetes-related morbidity and mortality. At a national level, diabetes drug 
adherence using average proportion of days covered (PDC) is estimated to 
range between 36% and 81%, with an estimated range for diabetes control 
between 38% and 47%. At a state level no such studies exist. 
OBJECTIVE: To estimate the level of medication adherence to antidiabetic 
agents and of diabetes control, and their association among patients with 
T2DM receiving medication treatment at the state and the Metropolitan 
Statistical Area (MSA) levels among the populations covered by commercial 
insurance, Medicare, or Medicaid. 
METHODS: The study population included adults with T2DM aged ≥18 years 
who were identified using ICD-9-CM code 250.xx, who received diabetes 
medication, and who were covered by private insurance, Medicare, or 
Medicaid in each state, the District of Columbia, and the top 50 MSAs. 
Medication adherence was measured by average PDC and the percentage 
of population that had a PDC ≥ 80%. Diabetes control was identified using 
ICD-9-CM diagnosis codes. Patients who were not diagnosed with uncon-
trolled diabetes (250.x2 and 250.x3) were identified as being under control. 
The administrative claims databases used for this study included the 2012 
medical and pharmacy claims from a large U.S. health plan, the complete 
2011 Medicare Standard Analytical File linked with Part D claims, and the 
2008 Mini-Medicaid Analytic eXtract (Mini-Max). Medication adherence and 
diabetes control were adjusted for age and sex to allow comparison across 
insurance coverage, states, and MSAs. 
RESULTS: For an insured patient population with T2DM that received dia-
betic drug treatment, average PDC was 79%. However, 35% of patients 
did not achieve an adherence of at least 80% of PDC. In addition, at least 
40% of patients did not have their diabetes under control. Across insur-
ance types, we found that patients insured with Medicare had relatively 
high average PDC and adherence levels (83% and 71%) in comparison 
with the commercially insured population (77% and 60%) and Medicaid 
patients (75% and 57%). In contrast, commercially insured patients had 
relatively better diabetes control (69%) than those insured with Medicare 
and Medicaid (54% and 53%, respectively). At a state level, we found that 
commercially insured and Medicare populations have relatively smaller 
geographic variation in drug adherence than the Medicaid population. 
CONCLUSIONS: This study identified gaps in T2DM drug adherence and 
pinpointed geographic areas that lag in terms of diabetes drug adherence 
or diabetes control and would benefit from implementing strategies to 
increase drug adherence. 
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RESEARCH
Medication nonadherence, particularly among patients with type 2 diabetes mellitus (T2DM), is a vital pub-lic health concern. Nonadherence is associated with 
morbidity and mortality and results in higher health care use 
and expenditures.1 In 2012, 29.1 million adults in the United 
States had diabetes, 90% of whom suffered from T2DM.2 
Among patients with T2DM, poor adherence to antidiabetic 
agents is strongly associated with suboptimal glycemic control 
and greatly increases the incidence of diabetes-related morbid-
ity and mortality and costs.3-5 Therefore, while the American 
Diabetes Association recommends individualized treatment 
targets, it does advise that for many nonpregnant adults, lower-
ing hemoglobin A1c (A1c) to below 7% is a reasonable goal.6 
Existing research has highlighted gaps in medication adher-
ence and diabetes control at the national level. A systematic 
review found that drug adherence among patients with T2DM 
in 4 nationally representative studies ranged between 36% and 
81%.7,8 Drug adherence, measured as the proportion of days 
covered (PDC), was 79% and 81% in 2 studies representative 
of pharmacy benefit organizations (PBO).7 The third study, 
using a large pharmacy claims database, used medication 
possession ratio as a proxy for drug adherence. This study 
• Diabetes drug adherence is strongly related to diabetes control 
and health outcomes. 
• There is a need to improve drug adherence and glycemic control. 
What is already known about this subject
• This study identifies gaps in drug adherence and diabetes control 
across insurance types, states, and Metropolitan Statistical Areas 
(MSAs).
• Adherence to oral and injectable antidiabetic medications varied 
significantly across states and MSAs, as well as insurance types. 
The Medicare population had the highest adherence, while the 
commercial population had the highest level of diabetes control, 
partially because of younger age and shorter disease duration. 
• States in the Northeast and Midwest regions were identified as 
doing better than the national averages in drug adherence and 
diabetes control, while southern states were found to have larger 
gaps in these care measures. 
What this study adds
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commercially insured patients was highest in the New England, 
Mid-Atlantic, East North Central, and West North Central 
states, which had 40% to 60% higher probability of being 
adherent to their medications than East South Central states. 
In this study, East North Central states included Wisconsin, 
Illinois, Indiana, Ohio, and Michigan. West North Central 
states included North and South Dakota, Nebraska, Kansas, 
Minnesota, Iowa, and Minnesota. East South Central states 
included Kentucky, Tennessee, Alabama, and Mississippi. In 
contrast, among the Medicare population with Part D benefits, 
New England and East North Central states were 8% to 19% 
more adherent than East South Central states. 
Our purpose in this claims-based retrospective cross-
sectional study was to examine the average PDC to antidiabetic 
agents, the percentage of optimal adherence, and the per-
centage of patients with controlled diabetes among patients 
diagnosed with T2DM who received antidiabetic medication. 
The results are presented at the state and MSA level for com-
mercially insured, Medicare, and Medicaid patients separately. 
■■  Methods
Data Sources
Data sources included the 2012 medical and pharmacy claims 
from UnitedHealth Group and non-UnitedHealth Group health 
plans (the deidentified Normative Health Information [dNHI] 
database), the 2011 Medicare Standard Analytical File medi-
cal claims linked with Part D claims from the 5% Chronic 
Conditions Data Warehouse files, and the 2008 Mini-Medicaid 
Analytic eXtract (Mini-Max), which is a one-time extraction 
of a 5% stratified random sample of the Medicaid population. 
These 3 databases were statistically deidentified. This study 
was reviewed and approved by an institutional review board 
and the Centers for Medicare & Medicaid Services (CMS) 
Privacy Review Board. 
Study Population
The study population included adults with T2DM who received 
diabetes medication and were covered by private insurance 
(aged 18 to 64 years), Medicare (aged 18 years and above), or 
Medicaid (aged 18 to 64 years) in each state, the District of 
Columbia, and the top 50 MSAs. For Medicare and Medicaid, 
only fee-for-service insured were included. The Medicare sam-
ple was limited to fee-for-service Part D enrollees and did not 
include Medicare Advantage Plans with Part D coverage. Adults 
with T2DM who filled an antidiabetic prescription any time 
during the year of data availability were included in the study. 
Patients were also required to be continuously covered during 
the entire calendar year. Patients with diagnosed diabetes were 
identified by 1 or more hospital stays or emergency department 
visits or at least 2 separate physician office or hospital outpa-
tient visits during which diabetes (International Classification 
of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 
excluded patients with T2DM who used insulin and found 69% 
of patients to be adherent.8 The fourth study, using a Medicaid 
population, concluded that drug adherence measured using 
PDC ranged between 36% and 49%.7 Diabetes control, defined 
by A1c below 7%, has been estimated to be 53% for commer-
cially insured patients and 62% for Medicare patients.5 To our 
knowledge, diabetes control for Medicaid patients is not cur-
rently available. 
Other studies have documented the wide geographic varia-
tions in general access to care, health care use, and expen-
ditures across the United States.9 For example, per capita 
diabetes-related medical expenditures in Massachusetts are 
1.4 times the expenditures in Utah.10 Regional differences in 
health care use, expenditures, and drug adherence are partially 
explained by population demographics, which include age, sex, 
and socioeconomic characteristics. Other important determi-
nants of population health care use are local, such as supply 
of care, financial incentives, practice patterns, and behavioral 
determinants of health. Furthermore, the degree of illness, out-
of-pocket drug costs, polypharmacy, complexity in drug regi-
men, and patients’ perceptions toward their illness and drug 
effectiveness are also known to affect adherence.11,12 
Little is known about the level of adherence to antidiabetic 
agents and its potential geographic variation at the state or 
Metropolitan Statistical Area (MSA) level. One previous study 
has found that adherence to oral antidiabetic medications 
varied significantly across 9 regions in the United States, after 
controlling for age, gender, socioeconomic status, and yearly 
out-of-pocket pharmacy expenses.13 This study concluded that 
diabetic drug adherence, captured by average PDC, among 
T2DM Population
Aged 18 to 64 years  
receiving FFS
Exclusion
Claims missing days  
of drug supply
T2DM Study Population
Receiving  
medication
• Commercial n = 224,248
• Medicare n = 254,664
• Medicaid n = 82,122
• Commercial n = 26,307
• Medicare n = 70,225
• Medicaid n = 12,119
• Commercial n = 197,941
• Medicare n = 184,439
• Medicaid n = 70,003
FIGURE 1 Flowchart of T2DM Patient Selection
Source: deidentified Normative Health Information database 2012, Medicare 2011, 
and Medicaid 2008.
FFS = fee for service; T2DM = type 2 diabetes mellitus. 
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code 250.xx) was recorded. T2DM patients were then identi-
fied using an algorithm described in Appendix A (available in 
online article). Using these criteria, we identified 561,034 indi-
viduals with T2DM across the 3 insurance categories (Figure 1). 
Excluded from this study were claims where number of days 
supplied were missing or zero or prescription fill dates were 
missing. The number of T2DM patients identified who received 
diabetes medication was 197,941 for commercially insured, 
184,439 for Medicare, and 70,003 for Medicaid (Figure 1). 
Study Measures
Drug adherence was measured using PDC, calculated as the pro-
portion of days with 1 or more drugs available during the study 
period. This period was defined as the time interval between 
the index date (the first script fill date during the study year) 
and the last day of the calendar year. We used an interval-based 
method to calculate a PDC for each patient using pharmacy 
claims.14 Upon calculating a PDC for each person, patients with 
a PDC ≥ 80% were classified as being adherent to their medica-
tions.15 We reported average PDC and adherence rates. 
Antidiabetic agents covered by the PDC calculations included 
oral antidiabetic drugs (OAD), including alpha-glucosidase 
inhibitors, meglitinides, biguanides, sulfonylureas, thiazoli-
dinediones, and dipeptidyl peptidase-4 inhibitors, and anti-
diabetic combinations, insulin mixes, long-acting insulins, and 
noninsulin injectable drugs (GLP-1 receptor agonists). Rapid-
acting insulin was excluded because of the uncertainty of the 
real days of supply. Days of supply for insulin and noninsulin 
injectable drugs were adjusted because of titration using exist-
ing method.16,17 Drug lists were constructed using Healthcare 
Effectiveness Data and Information Set-approved diabetes drugs 
by 2011 (the National Drug Code list available upon request).
Since our purpose was to examine general medication 
adherence to antidiabetic therapy, all drugs within antidiabetic 
agent drug classes were considered interchangeable. Days dur-
ing which concurrent drugs were supplied were only counted 
once. We adjusted fill dates and excluded inpatient days for 
PDC calculations following CMS Technical Notes.18 
The optimal way to measure diabetes control is through A1c 
values. While laboratory results are available for a subset of the 
commercially insured T2DM patients, Medicare and Medicaid 
files do not contain laboratory results. In order to create a con-
sistent definition of diabetes control across insurance types, we 
identified patients with controlled diabetes as those who were 
not diagnosed with uncontrolled diabetes (ICD-9-CM code 
250.x2 or 250.x3) during the study year. For the subset of com-
mercially insured T2DM patients for which we had both ICD-
9-CM and A1c information, we performed additional correla-
tion analyses to assert the strength of the association between 
the 2 measures of diabetes control. We found a strongly sig-
nificant and positive correlation between ICD-9-CM- and A1c-
based case identification measures (Spearman rank correlation 
coefficients of 0.22 [P < 0.001] for A1c > 9% as uncontrolled). 
Chi-square statistics were also significant.
Statistical Analysis 
Age group and sex specific average PDC and rates of adherence 
and control were calculated for each state/MSA and insurance 
type. State and MSA representative outcomes were generated by 
applying the T2DM rate and adherence and control measures to 
a representative T2DM population residing in each state/MSA. 
This population file was constructed combining demographics, 
medical insurance, and type of living arrangement information 
from the 2012 American Community Survey, diabetes preva-
lence for a community-based population from the 2011 and 2012 
 
Commercial Medicare Medicaid
Sample Size % Medication Sample Size % Medication Sample Size % Medication
T2DM patients receiving medication 197,941 88 184,439 73 70,003 82
Age group
18-34 7,177 89 4,953 74
35-44 26,505 90 9,794 82
45-54 65,419 89 23,500 84
55-59 48,269 87 16,373 86
60-64 50,571 85 15,383 79
< 65 39,238 76
65-69 32,100 76
≥ 70 113,101 70
Gender
Female 88,770 88 112,335 72 46,727 83
Male 109,171 89 72,104 73 23,276 79
T2DM = type 2 diabetes mellitus
TABLE 1 Sample Statistics of Patients with T2DM Receiving Antidiabetic Medication by Age and Gender
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Behavioral Risk Factor Surveillance System, and diabetes preva-
lence for a nursing home population from the 2004 National 
Nursing Home Survey. (Appendix B describes the construction 
of the MSA population files, available in online article.)
A Z-score was calculated to evaluate the standard deviation 
of each state’s/MSA’s adherence from the average PDC across 
states/MSAs. Spearman’s correlation coefficients were calcu-
lated between percentage adherent and percentage controlled. 
Statistical significance was determined using a P value below 
0.050. All analyses were performed using SAS version 9.3 (SAS 
Institute, Cary, NC).
■■  Results 
Across the 3 insurance types, 80% of patients received anti-
diabetic medication and constituted our study population. 
Respectively, 88%, 73%, and 82% of commercially insured 
patients, Medicare patients receiving Part D benefits, and 
Medicaid insured patients with T2DM received antidiabetic 
medication (Table 1). Among the commercially insured, 45% 
were female, while 61% and 67% were female among the 
Medicare and Medicaid insured, respectively. The majority 
used OAD drugs only: 73% for commercially insured, 64% for 
Medicare, and 68% for Medicaid.
At the national level, average PDC was 79% for our study 
population, and 65% of the population had an average PDC of 
80% or above. Average PDC and drug adherence increased by 
age: among commercially insured adults aged 18-34 years, the 
average PDC was 63%, while the average PDC for people aged 
70 years and above insured by Medicare was 84% (Table 2). On 
average, men had higher adherence than women using average 
PDC and level of adherence. While the difference was smallest 
among Medicare patients, the difference was statistically sig-
nificant: men had an average PDC of 83.2% (95% confidence 
interval [CI] = 83.0-83.3), while women had an average PDC of 
82.7% (95% CI = 82.6-82.9). Average PDC and drug adherence 
were higher for those patients insured by Medicare (83%, 95% 
CI = 82.9-83.1) than for those patients who were commercially 
insured (76.6%, 95% CI = 76.5-76.8) and Medicaid insured 
(74.4%, 95% CI = 74.2-74.6). 
Across the 3 insurance types, 60% of patients with T2DM 
receiving medication had their diabetes under control (Table 2). 
Between ages 18 and 64 years, the proportion of patients with 
their diabetes under control remained stable. However, for 
Medicare patients, diabetes control increased with age. Below 
aged 65 years, 46.6% (95% CI = 46.1-47.1) of the patients 
had their diabetes under control compared with 56.4% (95% 
CI = 56.1-56.6) of patients aged 70 years and above. Diabetes 
control was highest for commercially insured patients (68.9%, 
95% CI = 69.1-68.7) than for Medicare (53.7%, 95% CI = 53.5-
54.0) and Medicaid patients (52.7%, 95% CI = 52.3-53.0). 
Figure 2 displays the average PDC across states and insur-
ance types. Across the states, Medicaid patients experienced 
more variation in average PDC than Medicare or commer-
cially insured patients. Among commercially insured patients, 
Minnesota had the highest average PDC (85%), while Florida, 
Georgia, and Mississippi had the lowest average PDC (73%). For 
Commercial Medicare Medicaid
Mean 
(%)
Standard 
Error
Mean 
(%)
Standard 
Error
Mean 
(%)
Standard 
Error
Average PDC
Age group
18-34 63 0.003   64 0.004
35-44 70 0.002   70 0.003
45-54 76 0.001   75 0.002
55-59 79 0.001   79 0.002
60-64 82 0.001   81 0.002
<65  79 0.001  
65-69  84 0.001  
≥ 70  84 0.001  
Gender
Female 75 0.001 83 0.001 73 0.001
Male 78 0.001 83 0.001 76 0.002
Total 77 0.001 83 0.001 75 0.001
Percentage with PDC ≥ 80%
Age group
18-34 38 0.006   41 0.005
35-44 44 0.003   48 0.005
45-54 47 0.002   49 0.003
55-59 53 0.003   56 0.004
60-64 57 0.003   57 0.004
<65  63 0.002  
65-69  71 0.003  
≥70  73 0.001  
Gender
Female 57 0.002 70 0.001 55 0.002
Male 61 0.001 71 0.002 58 0.003
Total 60 0.001 71 0.001 57 0.002
Diabetes Control
Age group
18-34 67 0.006   54 0.007
35-44 68 0.003   52 0.005
45-54 67 0.002   52 0.003
55-59 68 0.002   52 0.004
60-64 68 0.002   52 0.004
<65   47 0.003  
65-69   54 0.003  
≥70   56 0.001  
Gender
Female 69 0.002 53 0.001 53 0.002
Male 68 0.001 54 0.002 53 0.003
Total 69 0.001 54 0.001 53 0.002
PDC = proportion of days covered; T2DM = type 2 diabetes mellitus.
TABLE 2 Average PDC, Drug Adherence Status, 
and Diabetes Control Status for Patients 
with T2DM Receiving Antidiabetic 
Medication by Insurance Type 
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Medicare patients, Maine, North Dakota, and Wyoming had the 
highest average PDC (87%), while the District of Columbia had 
the lowest average PDC (79%). For the Medicaid patients, Idaho, 
Montana, and Nebraska had the highest average PDC (82%), 
while Michigan had the lowest average PDC (61%). 
Among Medicare patients, the variation in percent adherent 
across states is smaller than the variation in percent adherent 
across states for Medicaid patients (Table 3). Percent adherent 
varied between 51% (Mississippi) and 74% (Minnesota) among 
the commercially insured; between 61% (District of Columbia) 
and 79% (Maine and North Dakota) among the Medicare 
patients; and between 33% (Kentucky) and 71% (Montana) 
among the Medicaid patients. Furthermore, the variation in 
percent adherent across states was larger than the variation 
in average PDC, suggesting that while average PDC may be 
similar, there is a larger variation in adherence if an adherence 
cutoff of 80% were used. 
At the state level, variation in diabetes control across states 
and insurance types are more apparent. Diabetes control among 
the commercially insured patients was higher than among the 
Medicare and Medicaid populations (Table 3). Average diabetes 
control ranged between 60% in Texas and Wyoming and 83% 
in Idaho among the commercially insured; between 44% in 
District of Columbia and New Mexico and 71% in Iowa and 
North Dakota among the Medicare patients; and between 50% 
in Texas and 60% in Arizona and Ohio among the Medicaid 
patients.
The correlation between the state adherence rate and diabe-
tes control was positive and significant for all insurance types. 
The correlation coefficient was smallest for the commercially 
insured patients (0.28, P = 0.043) and somewhat higher for 
the Medicare and Medicaid patients (0.49 and 0.56, P < 0.001, 
respectively). 
MSA variation in diabetes drug adherence and diabetes 
control followed a pattern similar to the state variation previ-
ously presented. Results for average PDC and diabetes control 
are available in Appendix F (available in online article). Average 
PDC is higher for the Medicare patients than for the Medicaid 
and commercially insured patients and experiences less varia-
tion in average PDC across MSAs. In contrast, diabetes control 
FIGURE 2 State Average PDC in Comparison to Average PDC Across States by Insurance Type and Overall
Note: The numbers in the legend represent the z-score. Blue states have an average PDC at least 1 standard deviation above the average PDC across states for that insur-
ance type. Green states have an average within 1 standard deviation from the average across states. Orange states have an average at least 1 standard deviation below the 
average across states. State-level sample sizes and average PDC statistics are available in Appendix C (available in online article). The figures do not include Alaska and 
Hawaii; only Hawaii’s Medicaid population has a standard deviation below the average across states.
PDC = proportion of days covered.
Commercial Medicaid
Medicare Overall
[-4, -1]
(-1, 1)
(1, 4)
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State
Drug Adherence Diabetes Control
Commercial
%
Medicare
%
Medicaid
%
All Three
%
Commercial
%
Medicare
%
Medicaid
%
All Three
%
Alabama 56 65 52 60 71 55 52 61 
Alaska 59 74 59 66 68 67 55 66 
Arizona 57 66 50 60 62 50 60 56 
Arkansas 57 70 48 62 79 62 51 67 
California 61 70 57 65 74 48 51 58 
Colorado 61 70 59 65 66 56 52 59 
Connecticut 61 72 61 66 70 54 53 61 
Delaware 62 75 56 68 70 52 53 59 
District of Columbia 56 61 33 56 68 44 53 55 
Florida 54 70 55 62 65 50 51 56 
Georgia 54 67 58 61 68 51 51 58 
Hawaii 59 73 51 65 72 60 52 64 
Idaho 61 71 67 66 83 66 55 71 
Illinois 61 72 55 66 68 54 52 60 
Indiana 60 69 57 65 73 56 51 62 
Iowa 70 77 61 73 79 71 53 72 
Kansas 65 76 50 69 73 62 52 65 
Kentucky 60 70 33 62 76 58 54 65 
Louisiana 55 67 59 61 72 53 52 60 
Maine 62 79 67 71 77 62 55 67 
Maryland 62 72 57 66 62 49 52 55 
Massachusetts 68 72 60 69 66 54 52 59 
Michigan 58 71 42 63 70 55 53 61 
Minnesota 74 78 56 74 81 69 52 72 
Mississippi 51 64 37 56 71 54 53 60 
Missouri 60 72 64 66 63 54 54 58 
Montana 66 75 71 71 81 62 57 69 
Nebraska 65 72 67 69 70 70 54 68 
Nevada 58 67 63 63 66 52 53 57 
New Hampshire 67 73 59 69 72 63 55 66 
New Jersey 62 74 59 67 67 49 53 57 
New Mexico 59 64 49 60 62 44 51 52 
New York 59 75 62 67 70 53 53 59 
North Carolina 58 69 53 63 70 54 51 60 
North Dakota 71 79 66 75 77 71 56 72 
Ohio 61 71 56 66 68 54 60 60 
Oklahoma 57 68 56 62 71 55 51 61 
Oregon 63 72 69 69 67 55 58 60 
Pennsylvania 64 74 67 69 68 58 54 61 
Rhode Island 69 68 60 68 71 54 55 61 
South Carolina 57 67 49 61 74 60 51 65 
South Dakota 68 78 61 72 81 66 55 71 
Tennessee 57 67 53 62 68 52 52 58 
Texas 55 66 51 60 60 45 50 51 
Utah 61 69 66 65 79 67 56 71 
Vermont 59 73 57 66 68 67 58 66 
Virginia 63 70 66 67 68 54 53 59 
Washington 64 73 55 67 70 54 53 60 
West Virginia 62 72 66 67 72 55 54 61 
Wisconsin 68 74 57 70 72 62 53 65 
Wyoming 66 77 60 71 61 63 57 62 
Average across states 61 71 57 66 71 57 53 62 
Note: The full table including standard errors for drug adherence and diabetes control and a map for diabetes control are presented in Appendices D and E (available in 
online article).
TABLE 3 Proportion of the Population Adherent to Medication and with Diabetes Control
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Limitations
This study has several limitations. First, the definition of dia-
betes control is based on ICD-9-CM codes and captures lack 
of control only when physicians identify a patient as such. We 
therefore compared the prevalence rate when using ICD-9-CM 
with the prevalence rate when using various A1c cutoffs. The 
ICD-9-CM-based prevalence rate overestimated controlled sta-
tus relative to the ADA’s recommended A1c level of below 7% 
for tight control (51%) but underestimated controlled status 
when using the Health Resources and Services Administration’s 
diabetes measure of poor control, which defines poor control 
with an A1c above 9%. While we do not have laboratory values 
available for the Medicare and Medicaid patients, we have no 
reason to suspect that coding would be different across insur-
ance population or across states. Future research should focus 
on validating the use of ICD-9-CM codes to identify diabetes 
control across these dimensions.
Second, we used claims from 1 large commercial plan only, 
which may not be representative of the insured population at 
subnational levels. These concerns are mitigated partially by 
reweighting the outcomes by age group and gender. Third, 
because of data limitations, only Medicare and Medicaid fee-
for-service beneficiaries were included in this study. States 
that have largely transitioned their Medicaid beneficiaries to 
managed care settings are often more complex. Fourth, some 
states suffered from small sample size problems including the 
commercial population in Alaska, Hawaii, and Vermont and 
the Medicaid population in Arizona. Ohio Medicaid claims 
did not include number of days supplied and therefore did 
not meet our selection criteria. Furthermore, our results were 
not adjusted for individual determinants of drug adherence 
other than age and gender. Income, race/ethnicity, health 
status, access to care, and provider treatment patterns could 
explain some of the geographic variation in outcomes that we 
highlight in this study. Understanding the significant drivers 
of geographic variation beyond those that can be explained by 
population demographics could shed light on creating more 
effective public health initiatives. 
Finally, it is important to note that the Affordable Care Act 
may have changed the landscape in diabetes care. Expanded 
coverage such as the further closing of the coverage gap in 
the Medicare “donut hole” and Medicaid expansion improves 
access to care and potentially increases the incentives for pre-
ventive care and medication adherence. Other factors, such as 
the emergence of high-deductible employer plans and the large 
deductibles and cost sharing featured by many individual plans 
purchased through health exchanges, should also be consid-
ered. The interplay of these new trends in the age of health care 
reform merits additional research.
■■  Conclusions
This study provides a detailed view of the adequacy of diabe-
tes management among the insured population across states 
was highest among the commercially insured patients and 
lowest among the Medicare patients. Variation in average PDC 
across MSAs was similar to the variation in average PDC across 
states. However, variation in diabetes control was larger at the 
MSA level than the state level. 
■■  Discussion
This study identifies gaps in drug adherence and diabetes con-
trol at the national, state, and MSA levels. Average PDC for an 
insured patient population with T2DM that received diabetic 
medication was 79%. However, for the same population, 1 in 3 
patients (35%) did not achieve at least 80% PDC. Furthermore, 
at least 40% of the insured patient population with T2DM that 
received diabetic medication did not have their diabetes under 
control. Average PDC for our 3 insurance populations ranged 
between 75% and 83%, suggesting little difference in adher-
ence across insurance categories. Our drug adherence results 
are comparable with 2 other nationally representative PBO 
populations.7 However, our Medicaid adherence results are 
higher than the 39% and 46% adherence for a Medi-Cal dataset 
using 1996-1998 data. 
Compared with the Medicaid (75%) and commercially 
insured population (77%), the Medicare insured patients had 
a significantly higher average PDC (83%). However, commer-
cially insured patients had better diabetes control (71%) than 
Medicare and Medicaid insured patients (57% and 53%, respec-
tively). The relationship between drug adherence and diabetes 
control is confounded by disease duration, which could explain 
why Medicare patients on average have high levels of drug 
adherence but low levels of diabetes control.19 At the same time, 
disease complications are more likely to arise as the disease 
progresses.20 As a result, elderly patients are more likely to have 
lower diabetes control despite higher levels of drug adherence, 
although for elderly patients, less stringent A1c levels may be 
more appropriate depending on their disease history. 
State- and MSA-level variation in drug adherence and dia-
betes control is relatively small for Medicare and commercially 
insured populations. For example, among the commercially 
insured population, average PDC ranged between 73% and 
85%, while diabetes control ranged between 60% and 83%. 
However, the Medicaid population experienced substantial 
variation in drug adherence across states (ranging between 
61% and 82%) but little variation in diabetes control (50%-
60%). Regional variations in drug adherence that we describe 
correspond to findings in earlier literature. Similar to the study 
by Couto et al. (2014),13 the states that correspond to the New 
England, Middle Atlantic, East North Central, and West North 
Central regions have higher antidiabetic medication adherence 
than East South Central states in the Medicare population. Our 
results for the commercially insured population also largely 
correspond to the results for the commercial population used 
in that study. 
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and MSAs. The significant and positive correlations between 
percentage of patients with optimal adherence and percentage 
with diabetes under control show that those states and MSAs 
with higher levels of adherence tend to have higher percentages 
of T2DM patients with control. The findings of this study high-
light the need to develop localized efforts in increasing diabetes 
drug adherence awareness and improving care. Physicians and 
other prescribers, insurers, and employers should identify and 
acknowledge potential barriers to adherence. They should strive 
to educate patients on why they need to fill their prescriptions, 
even when patients are asymptomatic, and communicate the 
consequences of lack of adherence on their health on an ongo-
ing basis. A systematic review concluded that continued multiple 
elements such as self-management plans, reinforcement, and 
occasionally rewards over time is a key element of success.21 
In particular, these efforts should concentrate on the states of 
Arizona, Georgia, New Mexico, and Texas, where diabetes drug 
adherence and diabetes control remain the lowest in the country. 
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APPENDIX A Type 2 Diabetes Sample Inclusion Criteria and Identification Algorithm
This appendix describes the inclusion and exclusion criteria that make up the sample of this study and describes the type 2 diabetes (T2DM) identification 
algorithm that was applied to the sample.
Inclusion criteria
•  Evidence of T2DM (see Type 2 Diabetes Identification Algorithm below).
•  Continuously enrolled in the fee-for-service coverage type of health plan (UnitedHealth Care, Medicare, Medicaid) during the measurement year. 
•  For diabetes patients with pharmacy claims or physician orders of prescriptions, ≥ 1 pharmacy claim for an antidiabetic medication.
Exclusion criteria
•  Patients aged < 18 years. 
•  Evidence of type 1 diabetes (T1DM; identified with ICD-9-CM diagnosis codes 250.x1 or 250.x3).
•  Evidence of gestational diabetes and/or pregnancy (if longitudinal approach is used during the 6-month baseline and follow-up periods).
Type 2 Diabetes Identification Algorithm
T2DM is defined as a patient who meets the following criteria using data during the measurement period:
•  ≥ 1 medical claim for T2DM (ICD-9-CM diagnosis codes 250.x0 or 250.x2) and no claims for T1DM, identified with ICD-9-CM diagnosis codes 250.x1 
or 250.x3. Diagnosis codes in the primary or secondary positions will be used. 
OR
•  If medical claims for both T1DM and T2DM, the patient must meet 1 of the following:
1. ≥ 1 claim for an oral antidiabetic drug (OAD) including sulfonylureas, metformin, thiazolidinediones, α-glucosidase inhibitors, meglitinide deriva-
tives, DPP-4 inhibitors, or combination of OADs with insulin or noninsulin injectable. 
OR
2. If no claims for OADs, the patient must have 4 or more claims for 250.xx with a valid fifth digit AND the number of claims for T2DM (250.x0, 
250.x2) must exceed the number of claims for T1DM (250.x1, 250.x3). 
OR
•  If no medical claims for 250.xx with a valid fifth digit, then the patient must have ≥1 claim for an OAD AND a claim for an injectable antidiabetic 
medication (GLP-1, pramlintide, or insulin) and no evidence of medical claims identifying T1DM patient in the previous year. 
OR
•  If no medical claims for 250.xx with a valid fifth digit and no claims for injectable antidiabetic medications, then the patient must have ≥1 claim for an 
OAD AND no medical claims with any of the following ICD-9-CM codes: 256.4, 272.6, 277.7, 648.8x, and 790.2x. These diagnosis codes are associ-
ated with diseases that require treatment similar to T2DM. As a result, we would be unable to ascertain that a patient was taking the drug for T2DM or 
another condition. Codes in any position will be used.
APPENDIX B Methods for Metropolitan Statistical Area Analysis 
This appendix details the multiple steps that were undertaken to create representative results at the Metropolitan Statistical Area (MSA) level. 
The first step involved creating a population file with a representative sample of the population residing in each county. The county files combined 
demographics, household income, medical insurance, and type of living arrangement information from the 2012 American Community Survey (ACS; 
n = 2,375,715); disease prevalence and health risk factors for a community-based population from the 2011 and 2012 Behavioral Risk Factor Surveillance 
System (BRFSS; n = 982,154); and disease prevalence and health risk factors for a nursing home population from the 2004 National Nursing Home Survey 
(NNHS; n = 14,017).
Using information on residence type, we divided the ACS population into those in nursing facilities to be matched to people in the NNHS and those not in 
nursing facilities to be matched to the BRFSS. For the noninstitutionalized population, each ACS individual was randomly matched with someone in the 
BRFSS from the same state, sex, age group (15 groups); race/ethnicity (non-Hispanic white, non-Hispanic black, non-Hispanic other, Hispanic); insured/
uninsured status; and household income level (8 levels). Individuals categorized as residing in a nursing home were randomly matched to a person in the 
NNHS in the same age group, sex, and race/ethnicity strata. The final matched ACS-BRFSS-NNHS database included a sample weight for each person. This 
weight reflected the number of people he or she represents among the general population.
Using U.S. Census Bureau 2012 data, we identified the current size of the population in each county by age, sex, and race/ethnicity. This county population 
database was merged with the Current Statistical Area Delineation file to aggregate counties to census-defined metropolitan areas. The county population 
files with the MSA definitions were then merged with the ACS-BRFSS-NNHS matched national population file to create a health and socioeconomic profile 
for a representative sample of adults in each of the selected 50 metropolitan areas. Finally, for each metropolitan area, the sample weights for the individu-
als in the merged file were re-weighted so that the weighted statistics matched the U.S. Census-published MSA demographic composition. Note that not all 
metropolitan areas correspond with federal designations. The New York-Newark-Jersey City, NY-NJ-PA, was split such that the NY numbers corresponded 
solely to the population in NY, with the NJ population placed in a constructed Northern NJ metropolitan designation. Likewise, Orange County, California, 
was carved out of the Los Angeles-Long Beach-Anaheim metropolitan area and reported separately. Similarly, West Palm Beach was reported separately from 
Miami-Fort Lauderdale, Florida (whereas the official designation of this metropolitan statistical area is Miami-Fort Lauderdale-West Palm Beach). 
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APPENDIX C Sample Size T2DM Receiving Antidiabetic Medication and Average PDC 
by State and Insurance Type
State
Sample Size Commercial Medicare Medicaid All Three
Commercial Medicare Medicaid Mean StdErr Mean StdErr Mean StdErr Mean StdErr
Alaska 42 209 156 76 0.04 84 0.01 75 0.02 80 0.00
Alabama 1,220 3,514 2,169 75 0.01 80 0.00 70 0.01 77 0.00
Arkansas 1,222 2,516 835 75 0.01 82 0.00 70 0.01 78 0.00
Arizona 5,528 1,971 43 75 0.00 81 0.01 70 0.04 77 0.00
California 14,169 16,093 7,440 78 0.00 83 0.00 76 0.00 80 0.00
Colorado 4,120 1,317 742 77 0.00 83 0.01 75 0.01 80 0.00
Connecticut 2,659 2,177 1,023 77 0.00 84 0.00 79 0.01 80 0.00
District of Columbia 565 317 570 76 0.01 79 0.01 64 0.01 76 0.00
Delaware 238 728 522 77 0.02 85 0.01 73 0.01 81 0.00
Florida 13,351 10,621 1,789 73 0.00 83 0.00 74 0.01 78 0.00
Georgia 27,574 5,474 2,924 73 0.00 81 0.00 76 0.00 77 0.00
Hawaii 47 569 370 77 0.03 84 0.01 71 0.01 80 0.00
Iowa 2,329 2,778 854 82 0.00 86 0.00 78 0.01 84 0.00
Idaho 244 795 534 78 0.02 83 0.01 82 0.01 81 0.00
Illinois 5,255 9,507 2,596 77 0.00 84 0.00 74 0.01 80 0.00
Indiana 2,563 4,880 2,292 76 0.00 83 0.00 74 0.01 79 0.00
Kansas 1,465 2,266 692 79 0.01 85 0.00 72 0.01 81 0.00
Kentucky 1,570 4,438 2,499 76 0.01 82 0.00 66 0.01 78 0.00
Louisiana 3,936 3,183 2,650 74 0.00 81 0.00 76 0.00 78 0.00
Massachusetts 1,467 4,112 1,428 81 0.01 84 0.00 76 0.01 82 0.00
Maryland 6,499 3,276 1,356 79 0.00 84 0.00 75 0.01 81 0.00
Maine 186 1,351 526 78 0.02 87 0.01 80 0.01 83 0.00
Michigan 1,379 6,338 340 75 0.01 83 0.00 61 0.02 77 0.00
Minnesota 5,779 1,877 860 85 0.00 86 0.00 75 0.01 85 0.00
Missouri 4,327 4,449 1,706 76 0.00 83 0.00 79 0.01 80 0.00
Mississippi 1,421 3,467 1,673 73 0.01 80 0.00 63 0.01 75 0.00
Montana 126 616 316 79 0.02 85 0.01 82 0.01 82 0.00
North Carolina 3,675 7,722 2,717 76 0.00 82 0.00 74 0.01 78 0.00
North Dakota 257 571 318 83 0.01 87 0.01 81 0.01 85 0.00
Nebraska 836 1,424 311 79 0.01 84 0.01 82 0.01 82 0.00
New Hampshire 293 832 335 80 0.01 84 0.01 75 0.01 81 0.00
New Jersey 8,176 5,893 1,131 78 0.00 85 0.00 78 0.01 81 0.00
New Mexico 980 1,193 473 76 0.01 81 0.01 72 0.01 78 0.00
Nevada 804 891 411 76 0.01 81 0.01 79 0.01 79 0.00
New York 21,020 9,748 7,506 76 0.00 85 0.00 78 0.00 81 0.00
Ohio 8,345 7,068 — 78 0.00 83 0.00 75 0.00 80 0.00
Oklahoma 3,086 2,979 1,179 75 0.00 82 0.00 75 0.01 78 0.00
Oregon 860 1,549 546 79 0.01 84 0.01 81 0.01 82 0.00
Pennsylvania 2,454 7,635 809 79 0.00 84 0.00 80 0.01 82 0.00
Rhode Island 1,524 568 215 81 0.01 82 0.01 78 0.02 81 0.00
South Carolina 1,330 3,377 1,277 74 0.01 81 0.00 69 0.01 77 0.00
South Dakota 128 731 296 81 0.02 86 0.01 76 0.01 83 0.00
Tennessee 2,819 4,799 2,915 75 0.00 81 0.00 73 0.00 78 0.00
Texas 20,952 13,793 4,923 74 0.00 81 0.00 72 0.00 77 0.00
Utah 861 732 320 77 0.01 82 0.01 80 0.01 80 0.00
Virginia 4,330 5,062 1,050 78 0.00 83 0.00 78 0.01 80 0.00
Vermont 41 537 301 76 0.04 86 0.01 76 0.01 81 0.00
Washington 1,385 3,205 1,246 79 0.01 83 0.00 75 0.01 81 0.00
Wisconsin 3,899 2,897 1,276 81 0.00 85 0.00 76 0.01 82 0.00
West Virginia 477 2,085 1,356 78 0.01 84 0.00 81 0.01 81 0.00
Wyoming 128 309 187 79 0.02 87 0.01 77 0.02 82 0.00
Average PDC across states 197,941 184,439 70,003 77 0.00 83 0.00 75 0.00 80 0.00
PDC = proportion of days covered; StdErr = standard error; T2DM = type 2 diabetes mellitus. 
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APPENDIX D Proportion of the Population Adherent to Medication and with Diabetes Control
State
Drug Adherence Diabetes Control
Commercial Medicare Medicaid All Three Commercial Medicare Medicaid All Three
Mean StdErr Mean StdErr Mean StdErr Mean StdErr Mean StdErr Mean StdErr Mean StdErr Mean StdErr
Alabama 56 0.01 65 0.01 52 0.01 60 0.01 71 0.01 55 0.01 52 0.01 61 0.01
Alaska 59 0.07 74 0.03 59 0.04 66 0.02 68 0.07 67 0.03 55 0.04 66 0.01
Arizona 57 0.01 66 0.01 50 0.07 60 0.01 62 0.01 50 0.01 60 0.07 56 0.01
Arkansas 57 0.01 70 0.01 48 0.01 62 0.01 79 0.01 62 0.01 51 0.02 67 0.01
California 61 0.00 70 0.00 57 0.00 65 0.00 74 0.00 48 0.00 51 0.01 58 0.01
Colorado 61 0.01 70 0.01 59 0.02 65 0.01 66 0.01 56 0.01 52 0.02 59 0.01
Connecticut 61 0.01 72 0.01 61 0.01 66 0.01 70 0.01 54 0.01 53 0.01 61 0.01
Delaware 62 0.03 75 0.02 56 0.02 68 0.01 70 0.03 52 0.02 53 0.02 59 0.01
District of Columbia 56 0.02 61 0.03 33 0.02 56 0.01 68 0.02 44 0.03 53 0.02 55 0.01
Florida 54 0.00 70 0.00 55 0.01 62 0.00 65 0.00 50 0.00 51 0.01 56 0.02
Georgia 54 0.00 67 0.01 58 0.01 61 0.00 68 0.00 51 0.01 51 0.01 58 0.00
Hawaii 59 0.07 73 0.02 51 0.03 65 0.02 72 0.07 60 0.02 52 0.03 64 0.01
Idaho 61 0.03 71 0.02 67 0.02 66 0.01 83 0.02 66 0.02 55 0.02 71 0.00
Illinois 61 0.01 72 0.00 55 0.01 66 0.00 68 0.01 54 0.01 52 0.01 60 0.00
Indiana 60 0.01 69 0.01 57 0.01 65 0.00 73 0.01 56 0.01 51 0.01 62 0.01
Iowa 70 0.01 77 0.01 61 0.01 73 0.01 79 0.01 71 0.01 53 0.02 72 0.00
Kansas 65 0.01 76 0.01 50 0.01 69 0.01 73 0.01 62 0.01 52 0.02 65 0.00
Kentucky 60 0.01 70 0.01 33 0.01 62 0.01 76 0.01 58 0.01 54 0.01 65 0.00
Louisiana 55 0.01 67 0.01 59 0.01 61 0.00 72 0.01 53 0.01 52 0.01 60 0.00
Maine 62 0.04 79 0.01 67 0.00 71 0.01 77 0.03 62 0.01 55 0.00 67 0.01
Maryland 62 0.01 72 0.01 57 0.01 66 0.00 62 0.01 49 0.01 52 0.01 55 0.01
Massachusetts 68 0.01 72 0.01 60 0.01 69 0.01 66 0.01 54 0.01 52 0.01 59 0.00
Michigan 58 0.01 71 0.01 42 0.02 63 0.01 70 0.01 55 0.01 53 0.02 61 0.02
Minnesota 74 0.01 78 0.01 56 0.01 74 0.00 81 0.01 69 0.01 52 0.02 72 0.00
Mississippi 51 0.01 64 0.01 37 0.01 56 0.01 71 0.01 54 0.01 53 0.01 60 0.01
Missouri 60 0.01 72 0.01 64 0.01 66 0.00 63 0.01 54 0.01 54 0.01 58 0.00
Montana 66 0.04 75 0.02 71 0.02 71 0.01 81 0.03 62 0.02 57 0.03 69 0.00
Nebraska 65 0.02 72 0.01 67 0.02 69 0.01 70 0.02 70 0.01 54 0.03 68 0.01
Nevada 58 0.02 67 0.02 63 0.02 63 0.01 66 0.02 52 0.02 53 0.02 57 0.00
New Hampshire 67 0.03 73 0.02 59 0.02 69 0.01 72 0.03 63 0.02 55 0.03 66 0.02
New Jersey 62 0.01 74 0.01 59 0.01 67 0.00 67 0.01 49 0.01 53 0.01 57 0.01
New Mexico 59 0.02 64 0.01 49 0.02 60 0.01 62 0.02 44 0.01 51 0.02 52 0.00
New York 59 0.00 75 0.00 62 0.00 67 0.00 70 0.00 53 0.01 53 0.01 59 0.01
North Carolina 58 0.01 69 0.01 53 0.01 63 0.00 70 0.01 54 0.01 51 0.01 60 0.01
North Dakota 71 0.03 79 0.02 66 0.02 75 0.01 77 0.03 71 0.02 56 0.03 72 0.02
Ohio 61 0.01 71 0.01 56 0.00 66 0.00 68 0.01 54 0.01 60 0.00 60 0.01
Oklahoma 57 0.01 68 0.01 56 0.01 62 0.01 71 0.01 55 0.01 51 0.01 61 0.01
Oregon 63 0.02 72 0.01 69 0.01 69 0.01 67 0.02 55 0.01 58 0.02 60 0.01
Pennsylvania 64 0.01 74 0.01 67 0.01 69 0.00 68 0.01 58 0.01 54 0.02 61 0.00
Rhode Island 69 0.01 68 0.02 60 0.03 68 0.01 71 0.01 54 0.02 55 0.03 61 0.01
South Carolina 57 0.01 67 0.01 49 0.01 61 0.01 74 0.01 60 0.01 51 0.01 65 0.00
South Dakota 68 0.04 78 0.02 61 0.02 72 0.01 81 0.03 66 0.02 55 0.03 71 0.00
Tennessee 57 0.01 67 0.01 53 0.01 62 0.00 68 0.01 52 0.01 52 0.01 58 0.01
Texas 55 0.00 66 0.00 51 0.01 60 0.00 60 0.00 45 0.00 50 0.01 51 0.01
Utah 61 0.02 69 0.02 66 0.02 65 0.01 79 0.01 67 0.02 56 0.02 71 0.01
Vermont 59 0.08 73 0.02 57 0.03 66 0.02 68 0.07 67 0.02 58 0.03 66 0.00
Virginia 63 0.01 70 0.01 66 0.01 67 0.00 68 0.01 54 0.01 53 0.01 59 0.01
Washington 64 0.01 73 0.01 55 0.01 67 0.01 70 0.01 54 0.01 53 0.01 60 0.01
West Virginia 62 0.02 72 0.01 66 0.01 67 0.01 72 0.02 55 0.01 54 0.01 61 0.01
Wisconsin 68 0.01 74 0.01 57 0.01 70 0.00 72 0.01 62 0.01 53 0.01 65 0.01
Wyoming 66 0.04 77 0.02 60 0.03 71 0.02 61 0.04 63 0.03 57 0.03 62 0.01
Average across states 61 0.00 71 0.00 57 0.00 66 0.00 71 0.00 57 0.00 53 0.00 62 0.00
StdErr = standard error.
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APPENDIX E Variation in Percentage of Diabetes Control Across Insurance Types and States
Note: The numbers in the legend represent diabetes control. Blue states have an average diabetes control of 70% or higher. Green states have an average diabetes control of 
60% to below 70%. Orange states have an average diabetes control below 60%. Diabetes control is highest among the commercially insured population and is lowest among 
the Medicaid population. All states, except Nebraska and Wyoming, have higher diabetes control among the commercially insured population than among the Medicare 
and Medicaid population. State-level sample sizes and diabetes control are available in Table 3 of this article. This figure does not include Alaska and Hawaii; those statis-
tics are available in Table 3.
Commercial Medicaid
Medicare Overall
[-4, -1]
(-1, 1)
(1, 4)
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APPENDIX F Sample Size of T2DM Receiving Antidiabetic Medication, Average PDC, 
and Diabetes Control by MSA and Insurance Type
This table presents average proportion of days covered (PDC) and percentage of diabetes control for each of the 50 Metropolitan Stastistical Areas (MSAs) 
included in this study. Similar to results at the state level, variation in diabetes control at the MSA level is larger than variation in average PDC. Average PDC 
ranges between 72% (Orlando, FL) and 84% (Minneapolis, MN) for commercially insured patients; 78% (Houston, TX) and 86% (Southern New Jersey, NJ) 
for Medicare insured patients; and 60% (Detroit, MI) and 82% (Orange County, CA) among Medicaid patients. In contrast, diabetes control varies between 
52% (San Antonio, TX) and 82% (Minneapolis, MN) for commercially insured patients; 37% (San Antonio, TX) and 68% (Minneapolis, MN) for Medicare 
patients; and 42% (Salt Lake City, UT) and 60% (Phoenix, AZ; Pittsburgh, PA; Las Vegas, NV; and Cleveland and Columbus, OH). 
For some metropolitan areas, the medical claims sample was small for some demographic groups (in particular the aged 20-34 years population). When the 
sample size fell below 30 adults for a particular demographic group, we used information for that same demographic group at the state or national level. For 
example, we did not identify any patients in the metropolitan areas and state level in Ohio. As a result, these statistics are based on the national age group 
and gender-adjusted estimates.
MSA, State
Sample Size of T2DM  
with Treatment Proportion of Days Covered Diabetes Control
Commer-
cial Medicare Medicaid 
Commercial Medicare Medicaid All Three Commercial Medicare Medicaid All Three
% Z-score % Z-score % Z-score % Z-score % StdErr % StdErr % StdErr % StdErr
Atlanta, GA 8,817 2,079 561 74 -1.24 80 -1.39 75 0.02 77 -1.33 66 0.01 48 0.01 49 0.02 55 0.01
Austin, TX 1,243 556 125 76 -0.28 82 -0.57 73 -0.41 79 -0.52 55 0.01 41 0.02 47 0.04 47 0.01
Baltimore, MD 1,423 1,683 659 81 1.49 83 0.49 75 0.05 81 1.05 61 0.01 48 0.01 48 0.02 53 0.01
Boston, MA 1,538 2,617 860 81 1.54 84 1.07 77 0.68 82 1.50 64 0.01 55 0.01 48 0.02 58 0.01
Charlotte, NC 1,203 1,524 295 75 -0.76 82 -0.13 72 -0.78 78 -0.65 70 0.01 58 0.01 48 0.03 61 0.01
Chicago, IL 2,303 6,203 1,674 76 -0.40 83 0.31 74 -0.10 79 -0.09 70 0.01 52 0.01 48 0.01 58 0.01
Cincinnati, OH 2,271 1,069 78 78 0.34 82 -0.36 71 -0.98 79 -0.22 77 0.01 58 0.01 54 0.06 65 0.01
Cleveland, OH 831 1,128 — 76 -0.33 82 -0.11 75 0.04 79 -0.22 71 0.02 55 0.01 60 0.00 62 0.01
Columbus, OH 1,208 867 — 79 0.62 84 1.08 75 0.04 81 0.86 63 0.01 44 0.02 60 0.00 53 0.01
Dallas, TX 6,296 2,823 665 74 -1.10 81 -0.97 77 0.44 78 -0.96 62 0.01 47 0.01 48 0.02 53 0.02
Denver, CO 2,041 412 201 78 0.24 81 -0.84 76 0.23 79 -0.22 64 0.01 49 0.02 49 0.03 55 0.00
Detroit, MI 349 2,608 98 75 -0.96 82 -0.10 60 -4.05 77 -1.52 69 0.02 48 0.01 51 0.05 56 0.01
Hartford, CT 1,070 714 365 77 -0.05 84 0.63 75 0.03 80 0.28 71 0.01 54 0.02 50 0.02 60 0.00
Houston, TX 2,637 2,219 901 74 -1.25 78 -2.66 70 -1.36 76 -2.27 60 0.01 41 0.01 50 0.02 49 0.00
Indianapolis, IN 793 1,127 321 77 -0.05 83 0.55 70 -1.18 79 -0.04 72 0.02 53 0.01 49 0.03 60 0.01
Jacksonville, FL 887 749 95 73 -1.62 81 -0.82 74 -0.30 77 -1.34 71 0.02 52 0.02 55 0.05 60 0.00
Kansas City, MO 1,125 1,010 281 79 0.66 82 -0.11 75 0.17 80 0.34 69 0.01 56 0.01 48 0.03 60 0.00
Las Vegas, NV 345 580 — 76 -0.39 81 -1.20 75 0.04 78 -0.78 62 0.03 46 0.02 60 0.00 54 0.00
Los Angeles, CA 2,575 4,539 2,172 77 0.06 83 0.17 75 0.14 80 0.14 77 0.01 45 0.01 49 0.01 58 0.00
Memphis, TN 538 877 378 73 -1.51 79 -2.24 69 -1.53 76 -2.25 62 0.02 46 0.02 49 0.03 52 0.01
Miami, FL 2,342 3,040 78 73 -1.42 83 0.48 74 -0.25 79 -0.59 67 0.01 44 0.01 56 0.05 54 0.01
Milwaukee, WI 1,873 784 428 81 1.47 82 -0.23 69 -1.60 80 0.30 71 0.01 57 0.02 48 0.02 62 0.00
Minneapolis, MN 2,998 830 432 84 2.98 85 1.50 73 -0.53 83 2.20 82 0.01 68 0.02 48 0.02 71 0.02
Nashville, TN 493 762 255 77 -0.03 81 -0.99 72 -0.72 78 -0.66 62 0.02 45 0.02 47 0.03 52 0.00
New York, NY 21,432 10,938 5,121 76 -0.25 85 1.52 79 1.12 81 0.85 70 0.00 50 0.00 47 0.01 57 0.01
Norfolk, VA 275 763 95 75 -0.65 82 -0.55 75 -0.05 78 -0.63 57 0.03 49 0.02 56 0.05 53 0.00
Northern New Jersey, NJ 8,495 4,494 729 78 0.37 84 1.17 78 0.75 81 0.94 66 0.01 49 0.01 47 0.02 55 0.00
Oklahoma City, OK 1,268 713 232 76 -0.48 83 0.05 77 0.69 79 -0.07 70 0.01 55 0.02 48 0.03 60 0.01
Orange County, CA 911 1,092 206 79 0.84 85 1.49 82 1.93 82 1.62 73 0.01 47 0.01 43 0.03 56 0.00
Orlando, FL 1,850 1,046 121 72 -2.01 81 -0.69 77 0.51 77 -1.29 64 0.01 50 0.01 53 0.04 56 0.02
Philadelphia, PA 673 3,282 346 79 0.81 84 0.69 73 -0.44 81 0.66 68 0.02 55 0.01 49 0.02 59 0.01
Phoenix, AZ 3,053 986 15 75 -0.69 82 -0.33 75 0.04 79 -0.52 60 0.01 47 0.01 60 0.13 53 0.00
Pittsburgh, PA 159 714 17 80 1.05 83 0.48 75 0.04 81 0.81 67 0.04 56 0.02 60 0.12 61 0.01
Portland, OR 1,020 523 239 78 0.45 84 0.91 78 0.86 81 0.88 66 0.01 53 0.02 48 0.03 57 0.01
Providence, RI 2,699 1,120 298 81 1.60 84 0.75 78 0.82 82 1.41 70 0.01 57 0.01 46 0.03 61 0.02
Raleigh, NC 565 555 120 76 -0.46 83 0.20 77 0.51 79 -0.03 73 0.02 52 0.02 51 0.04 60 0.01
Richmond, VA 755 832 69 78 0.26 82 -0.47 77 0.60 80 0.06 68 0.02 53 0.02 58 0.06 59 0.01
Riverside, CA 1,255 1,251 659 76 -0.41 82 -0.42 74 -0.12 79 -0.45 74 0.01 43 0.01 49 0.02 56 0.01
Sacramento, CA 596 633 500 80 1.03 83 0.14 77 0.69 81 0.78 68 0.02 45 0.02 47 0.02 54 0.00
Salt Lake City, UT 861 292 130 77 -0.05 81 -0.89 81 1.76 79 -0.04 75 0.01 63 0.03 42 0.03 65 0.01
San Antonio, TX 2,275 796 519 76 -0.56 78 -2.65 75 0.05 77 -1.56 52 0.01 37 0.02 48 0.02 44 0.00
San Diego, CA 1,012 934 436 79 0.63 82 -0.10 78 0.83 80 0.49 74 0.01 55 0.02 48 0.02 61 0.00
San Francisco, CA 1,183 1,548 617 79 0.86 85 1.47 81 1.59 82 1.55 74 0.01 50 0.01 47 0.02 59 0.01
Seattle, WA 1,395 1,314 526 79 1.00 84 0.83 75 0.00 81 0.94 68 0.01 53 0.01 47 0.02 58 0.01
Southern Connecticut, CT 2,373 1,054 464 79 0.88 83 0.50 80 1.36 81 1.04 71 0.01 54 0.01 44 0.02 60 0.01
Southern New Jersey, NJ 354 971 180 77 -0.13 86 1.79 79 1.09 81 1.05 71 0.02 51 0.01 48 0.04 58 0.00
St. Louis, MO 2,867 1,694 442 77 -0.05 83 0.26 73 -0.61 79 -0.05 61 0.01 48 0.01 47 0.02 53 0.01
Tampa, FL 4,089 1,202 203 74 -1.22 83 0.45 73 -0.48 79 -0.56 61 0.01 48 0.01 50 0.03 53 0.01
Washington, DC 3,979 1,972 862 78 0.57 83 0.02 70 -1.42 80 -0.02 66 0.01 48 0.01 49 0.02 55 0.01
West Palm Beach, FL 1,706 721 50 74 -1.39 82 -0.20 74 -0.22 78 -0.90 65 0.01 51 0.02 59 0.07 57 0.01
Average across MSAs 114,299 82,240 24,118 77 N/A 83 N/A 75 N/A 80 N/A 67 0.00 51 0.00 50 0.00 57 0.00
MSA = Metropolitan Statistical Area; N/A = not applicable; PDC = proportion of days covered; StdErr = standard error; T2DM = type 2 diabetes mellitus.
